pharmaceutical investing Ritter Pharmaceuticals Completes Dosing of Last Patient in Pivotal 557-Subject Phase 3 Clinical Trial
pharmaceutical investing Ritter Pharmaceuticals Completes Enrollment in Pivotal Phase 3 Clinical Trial of RP-G28 in Patients with Lactose Intolerance
Quantum BioPharma Announces Cash Reward of up to USD $7Million for Proof of Market Manipulation in its Stock
UPDATE - Critical Metals Corp (NASDAQ: CRML) Secures Another Significant Tanbreez Offtake Agreement for 15% of its Production with Leading U.S. Vertically Integrated Rare Earth Company, REalloys Inc.
